Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iRhythm Technologies, Inc.

http://www.irhythmtech.com/

Latest From iRhythm Technologies, Inc.

Medtech DEI Experts Talk Shop: ‘It’s Going To Transform Businesses’

An all-female panel of medtech DEI leaders at the LSX Congress USA conference discussed the importance of diversity and inclusion in research, clinical trials, product development and services to advance health equity as well as fundamental business goals.

Diversity & Inclusion Business Strategies

Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.

Artificial Intelligence Business Strategies

Cardio Conversations: iRhythm Prepares To Deliver ‘Standard-Of-Care’ Cardiac Monitoring

Quentin Blackford, CEO of iRhythm, talked to Medtech Insight about his company’s plans to bring its Zio long-term cardiac monitoring platform to more patients by building its evidence base and marketing in more countries outside the US.

Cardio Conversations Patient Monitoring

News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use

This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.

Commercial Policy
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Monitoring Equipment & Devices
UsernamePublicRestriction

Register